Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | IDO1 | P14902 | 3/20 | 0.43 |
| ▸ | NOS1 | P29475 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | AXL | P30530 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | WEE1 | P30291 | 1/20 | 0.40 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7572936 | 0.80 | IDO1 (0.43) | MAPTIDO1NOS1KDM4EAXL | |
| SCHEMBL8404436 | 0.79 | IDO1 (0.46) | MAPTIDO1NOS1AXLCCNA2 | |
| SCHEMBL12439133 | 0.79 | IDO1 (0.46) | MAPTIDO1NOS1KDM4EAXL | |
| SCHEMBL27228475 | 0.78 | AXL (0.43) | MAPTIDO1NOS1KDM4EAXL | |
| SCHEMBL19657811 | 0.76 | NOS1 (0.50) | MAPTIDO1NOS1AXLCCNA2 | |
| SCHEMBL3535709 | 0.76 | NOS1 (0.55) | MAPTIDO1NOS1KDM4EAXL | |
| SCHEMBL12821601 | 0.76 | NOS1 (0.55) | MAPTIDO1NOS1KDM4EAXL | |
| SCHEMBL9909086 | 0.76 | TRPA1 (0.47) | IDO1NOS1AXLCDK2CCNA1 | |
| SCHEMBL4133588 | 0.76 | NOS1 (0.50) | IDO1NOS1AXLCCNA2CDK2 | |
| SCHEMBL16647168 | 0.76 | IDO1 (0.47) | MAPTIDO1NOS1AXLCCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0904769-B1 | Keratin fibre dye compositions containing Indazole amine derivatives and dyeing method | OREAL (FR) | 2002-09-25 | — | — | EP | claimed |
| WO-2024199524-A1 | COMPOUND AS PKMYT1 INHIBITOR | 江苏星盛新辉医药有限公司 | 2024-10-03 | — | — | WO | disclosed |
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024073073-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2022192790-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022111513-A1 | AROMATIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 杭州多域生物技术有限公司 | 2022-06-02 | — | — | WO | disclosed |
| US-7662821-B2 | improved selectivity and pharmacokinetic properties; 6-Fluoro-1-[(1 H-indazol-4-yl)amino]-4,4-dimethyl-2-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalene-2,5-diol; cyclization of imines | BAYER SCHERING PHARMA AG (DE) | 2010-02-16 | — | — | US | disclosed |
| US-7659297-B2 | improved selectivity and pharmacokinetic properties; 6-Fluoro-1-[(1 H-indazol-4-yl)amino]-4,4-dimethyl-2-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalene-2,5-diol; cyclization of imines | Bayer Schering Pharma, AG (DE) | 2010-02-09 | — | — | US | disclosed |
| US-7638515-B2 | improved selectivity and pharmacokinetic properties; 6-Fluoro-1-[(1 H-indazol-4-yl)amino]-4,4-dimethyl-2-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalene-2,5-diol; cyclization of imines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-12-29 | — | — | US | disclosed |
| EP-1670458-B1 | 1-AMINO-2-OXY-SUBSTITUTED TETRAHYDRONAPHTALENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, AND THEIR USE AS ANTIPHLOGISTICS | SCHERING AG (DE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005034939-A1 | 1-AMINO-2-OXY-SUBSTITUTED TETRAHYDRONAPHTALENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, AND THEIR USE AS ANTIPHLOGISTICS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-21 | — | — | WO | disclosed |
| WO-2005003098-A1 | HETEROCYCLICALLY SUBSTITUTED PENTANOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-01-13 | — | — | WO | disclosed |
| US-6027538-A | OXIDATION DYEING OF KERATINOUS FIBERS CONTAINING AT LEAST ONE COUPLER SELECTED FROM INDAZOLEAMINE DERIVATIVES AND AT LEAST ONE OXIDATION BASE; POWERFUL, NOT VERY SELECTIVE HAIR DYES WHICH ARE CAPABLE OF GENERATING INTENSE COLOR | L'OREAL S.A. (FR) | 2000-02-22 | — | — | US | disclosed |
| US-4608383-A | Cardioactive pyrazole and imidazole aryloxypropanolamines | BOEHRINGER MANNHEIM GMBH (DE) | 1986-08-26 | — | — | US | disclosed |
| EP-0042593-B1 | ARYLOXY-PROPANOL AMINES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS | Roche Diagnostics GmbH (DE) | 1985-04-03 | — | — | EP | disclosed |
| US-4507488-A | N-Pyrazolylalkylenediamine intermediates | BOEHRINGER MANNHEIM GMBH (DE) | 1985-03-26 | — | — | US | disclosed |
| EP-0042592-B1 | N-HETEROARYLALKYLENE DIAMINES, PROCESS FOR THEIR PREPARATION AND THEIR USE | Roche Diagnostics GmbH (DE) | 1985-01-30 | — | — | EP | disclosed |
| US-4438128-A | ADRENERGIC BLOCKERS | BOEHRINGER MANNHEIM GMBH (DE) | 1984-03-20 | — | — | US | disclosed |
| EP-0042592-A1 | N-heteroarylalkylene diamines, process for their preparation and their use | Roche Diagnostics GmbH (DE) | 1981-12-30 | — | — | EP | disclosed |
| EP-0042593-A1 | Aryloxy-propanol amines, process for their preparation and medicines containing these compounds | Roche Diagnostics GmbH (DE) | 1981-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | LRRK2, MAP3K20, MAP3K5 | MAPT 623/4885IDO1 2631/4885NOS1 4272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.